Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$156.66-2.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
Research Workspace
Put ALNY beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Achieve $4.9B-$5.3B revenue in 2026: Revenue guidance: $4.2B to $4.5B.
View ThesisRevenue growth is accelerating — up about 56% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 67% in its worst 12-month stretch.
View RiskAlnylam's TTR franchise growth has to keep compounding to justify the price. Revenue grew 17% year over year in the latest quarter. The company beat its earnings estimate by 1013.7%. It trades at 8.0 times earnings versus a 20.8 times peer median. The price reflects less growth than we forecast. Revenue guidance of $4.2B to $4.5B is below the $4.9B target. This specific gap breaks the primary thesis pillar. Peer multiples imply a price about 39% above where it trades. The thesis has broken. This read is provisional.
Trailing returns as of 2026-11-05. ALNY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 31 analysts currently covering ALNY (as of Nov 2026).
Based on 13 Wall Street analysts offering 12-month price targets for ALNY in the last 4 months.
Continue this research
Compare ALNY with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ALNY Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ALNY next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Capital return signals confidence in cash flow.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-05. EPS is implied from price ÷ P/E. Not investment advice.
Current $156.66
The last 12 months of price, then the range of analyst 12-month targets from today’s $156.66.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Grow TTR franchise and expand AMVUTTRA access
Analyst downgrade signals skepticism on core growth driver.
Threatens: Achieve $4.2B-$4.5B total TTR net product revenues in 2026
Medicare access concerns and pipeline delays threaten TTR growth and confidence in delivery.
Advances: Achieve $4.2B-$4.5B total TTR net product revenues in 2026
Reiterates the 2026 TTR sales target; expanded trial enrollment preserves the stated launch timeline.
Advances: Achieve $4.2B-$4.5B total TTR net product revenues in 2026
TTR growth supports revenue guidance despite trim.
Advances: Achieve $4.9B-$5.3B revenue in 2026
Supports revenue growth across ATTR patient groups.
Threatens: Achieve $4.9B-$5.3B revenue in 2026
Concerns over silencer drug could impact revenue projections.
Advances: Expand TTR Franchise revenues to $4.2B-$4.5B in 2026
Positive data supports TTR franchise revenue growth.
